Insight Molecular Diagnostics (IMDX) Investor presentation summary

Mission and business model

• Aims to decentralize access to novel molecular diagnostic testing, improving patient outcomes by empowering local labs to conduct in-house testing with kits rather than relying on central labs.

• Business model leverages high-value recurring revenue, high reimbursement rates, and strong IP protection to drive profitability and long-term customer value.

• Focuses on precision medicine, rapid and localized care, and point-of-care diagnostics using liquid biopsy and digital PCR technologies.

Product portfolio and innovation

• Flagship product GraftAssureDx targets transplant monitoring, with a pipeline including GraftAssureCore, GraftAssureIQ, and oncology-focused assays.

• RUO kits launched in 2024, with revenue beginning in Q2 2025 and FDA IVD submission for clinical use planned for March 2026.

• Products are designed to be organ-agnostic, supporting rapid expansion into heart and other transplant testing.

Market opportunity and clinical demand

• Regulated transplant testing represents a $2B+ global opportunity, with high clinical demand for decentralized donor-derived cell-free DNA (dd-cfDNA) testing.

• U.S. Medicare reimbursement for GraftAssureCore is $2,753 per result, supporting strong economics.

• Estimated TAM for heart transplant testing is $105M in the U.S. and $240M globally, with higher testing frequency and clinical stakes.